SKP-0141

SKP-0141 is a human plasma-derived Factor VIII replacement therapy developed for the treatment and prophylaxis of Hemophilia A. It is classified as an antihemorrhagic agent and blood coagulation factor, specifically designed to replace deficient or absent Factor VIII in patients with Hemophilia A. The drug is administered intravenously and aims to prevent or control bleeding episodes in individuals with severe Hemophilia A (Factor VIII level < 1%). Clinical studies focus on previously treated male patients aged 12 to 65 years, evaluating efficacy primarily through annualized bleeding rates during prophylactic treatment[1][2][3][5]. The mechanism of action involves direct replacement of missing Factor VIII, thereby restoring normal blood clotting function.

Other names

SKP 0141SKP0141SKP-0141